Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AllerT pre-seasonal dosing trial in adults with birch pollen allergic rhinitis/rhinoconjunctivitis
2016-000076-23Phase 2Completed
- Sponsor
- Anergis
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cetirizine in birch pollen allergy, allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (3 arms), sponsored by Anergis. Primary endpoint: Average combined Rhinoconjunctivitis Symptom and Medication Score. Started May 2016; status: completed.
02
Drugs
cetirizine
03
Conditions
birch pollen allergyallergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2016-000076-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000076-23.